FindTrial
Sign In

A national multicentre retrospective study of beliuzumab in the treatment of Chinese children with systemic lupus erythematosus

A national multicentre retrospective study of beliuzumab in the treatment of Chinese children with systemic lupus erythematosus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050041
Enrollment
Unknown
Registered
2021-08-16
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic Lupus Erythematosus in children

Interventions

belimumab group :treated with belimumab
Dmards group:treated with Dmards

Sponsors

Guangzhou Women's and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Children aged 5 to 18 years who were diagnosed with systemic lupus erythematosus and received beliuzumab at least 8 times between 2019.9.1~2021.6.1(including children who stopped using beliuzumab due to lost follow-up, or allergy, or infection, but had follow-up data for more than one dose); 2.Simultaneous hospitalization of children with SLE treated with traditional regimens.

Exclusion criteria

Exclusion criteria: Participate in clinical trials of other treatment studies during the study period.

Design outcomes

Primary

MeasureTime frame
Systemic lupus erythematosus disease activity score SLEDAI-2K;—

Secondary

MeasureTime frame
IgG;CD3+;CD4+;CD19+;dosage of Glucocorticoid;Weight;symptom;antinuclear antibody;—

Countries

China

Contacts

Public ContactZeng Ping

Guangzhou Women's and Children's Medical Center

zengpingtom@126.com+86 13160897678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026